ESALY.PK

Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting

Wednesday, April 14, 2021 - 5:49am

b"TOKYO, Apr 14, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will conduct presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401), its dual orexin receptor antagonist lemborexant (product name: Dayvigo) and its antiepileptic drug perampanel (product name: Fycompa), at the Virtual American Academy of Neurology (AAN 2021) Annual Meeting from April 17 to 22, 2021.\nAs major presentations, an oral presentation regarding lecanemab will be given on the preliminary analysis for results of changes in brain-A beta levels and amyloid-related imaging abnormalities-edema (ARIA-E) as observed in subjects of the ongoing open-label extension of the Phase II study (Study 201) for early Alzheimer's disease (AD) patients.

Key Points: 
  • b"TOKYO, Apr 14, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will conduct presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401), its dual orexin receptor antagonist lemborexant (product name: Dayvigo) and its antiepileptic drug perampanel (product name: Fycompa), at the Virtual American Academy of Neurology (AAN 2021) Annual Meeting from April 17 to 22, 2021.\nAs major presentations, an oral presentation regarding lecanemab will be given on the preliminary analysis for results of changes in brain-A beta levels and amyloid-related imaging abnormalities-edema (ARIA-E) as observed in subjects of the ongoing open-label extension of the Phase II study (Study 201) for early Alzheimer's disease (AD) patients.
  • Poster presentations regarding lemborexant are also planned, including the results of a pilot study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment.
  • Additionally, for perampanel, a global pooled analysis results from the real-world experiences including early adjunctive use or monotherapy will be presented at poster sessions.\nEisai considers neurology a therapeutic area of focus.
  • Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with the disease and their families.\n"

KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries

Wednesday, March 31, 2021 - 1:22pm

Based on this agreement, Eisai will acquire exclusive development and marketing rights from KYORIN for the agent in the said four countries, and will be responsible for submitting a New Drug Application for the agent.

Key Points: 
  • Based on this agreement, Eisai will acquire exclusive development and marketing rights from KYORIN for the agent in the said four countries, and will be responsible for submitting a New Drug Application for the agent.
  • Overactive bladder (OAB) is the name for a group of urinary symptoms characterized by urinary urgency, usually accompanied by increased daytime frequent urination and/or nocturia, and in some cases by urge urinary incontinence.
  • KYORIN has been making a contribution to improving the quality of life of patients with OAB through early penetration of the agent into the Japanese market.
  • With the execution of this agreement, KYORIN will now work with Eisai to make the agent available in the licensed territory and promote the expansion of its business internationally.

Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan

Wednesday, March 31, 2021 - 1:18pm

TOKYO, Mar 31, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K.

Key Points: 
  • TOKYO, Mar 31, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K.
  • This is the first application to be submitted in Japan for this combination therapy.
  • In this trial, LENVIMA plus KEYTRUDA demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of progression-free survival (PFS) as well as key secondary endpoints of overall survival (OS) and objective response rate (ORR) versus sunitinib.
  • The safety profile of LENVIMA plus KEYTRUDA was consistent with previously reported studies.

Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab

Tuesday, March 30, 2021 - 4:42am

The safety profile of the lenvatinib plus pembrolizumab combination in these studies was generally consistent with previously reported studies.

Key Points: 
  • The safety profile of the lenvatinib plus pembrolizumab combination in these studies was generally consistent with previously reported studies.
  • Worldwide, it is estimated that there were more than 430,000 new cases of kidney cancer diagnosed and nearly 180,000 deaths from the disease in 2020.
  • (1) RCC is by far the most common type of kidney cancer; about nine out of 10 kidney cancers are RCC.
  • (3),(4)
    In 2020, it is estimated there were more than 417,000 new cases of uterine body cancer diagnosed worldwide and nearly 97,000 deaths from the disease.

Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021

Friday, March 26, 2021 - 12:16am

TOKYO, Mar 26, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel (brand name: FYCOMPA, "perampanel"), the AMPA-type glutamate receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2021 by the PSJ.

Key Points: 
  • TOKYO, Mar 26, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel (brand name: FYCOMPA, "perampanel"), the AMPA-type glutamate receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2021 by the PSJ.
  • The reasons for the selection of this discovery research for the award are outlined by the PSJ as follows.
  • Although glutamate receptors, which are responsible for neuronal excitation, have long been recognized as important drug discovery targets, they have not led to the creation of any drugs.
  • It has been demonstrated that perampanel is a selective, non-competitive AMPA receptor antagonist.

Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan

Tuesday, March 23, 2021 - 9:34am

TOKYO, Mar 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.

Key Points: 
  • TOKYO, Mar 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.
  • This marks the first approval for LENVIMA for unresectable thymic carcinoma in Japan.
  • For unresectable thymic carcinoma, platinum-based first-line therapy is recommended.
  • In June 2020, LENVIMA received orphan drug designation in Japan for unresectable thymic carcinoma.